Shenzhen Hepalink Pharmaceutical Co., Ltd. [002399.SZ] announced  that it has entered into a stock purchase agreement to acquire Scientific Protein Laboratories, LLC. (SPL), a leading global, independent manufacturer and supplier of active pharmaceutical ingredients (APIs). With the acquisition, Hepalink will expand its presence as one of the leading suppliers of heparin worldwide, while providing the combined company with greater product development and growth opportunities in new markets for its full line of APIs, including pancreatic enzyme and heparin products. This acquisition allows for greater investment in R&D, new products and processes, and will form a stronger company with enhanced cutting-edge R&D capabilities in the global heparin API sector. 

Under the terms of the agreement, Hepalink has agreed to acquire SPL for US$337.5 million in cash plus certain contingent payments.